Drug or treatment

Polatuzumab clinical trials

• 24Clinical trials
• 2New in 30 days
• 18Countries

Newest trials

All recruiting trials (24)

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Holding/bridging therapy with a bispecific antibody before CAR-T in aggressive B-cell lymphoma

  This study tests whether a short course of a CD20×CD3 bispecific antibody, given with GemOx or polatuzumab vedotin, helps patients with relapsed or refractory aggressive B-cell lymphoma proceed to planned CD19 CAR-T therapy.

  Recruiting Phase 2 National Research Center for Hematology, Russia · Moscow, Moscow · NCT07883135

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Pola-ZR-Glo for older patients with large B‑cell lymphoma

  This trial will try combining polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab as first-line treatment for people aged 70 and older with newly diagnosed large B‑cell lymphoma who are unfit for standard chemo or decline immunochemotherapy.

  Recruiting Phase 2 Ruijin Hospital · Shanghai · NCT07514169

• CRP regimen for older adults with untreated double‑expressor diffuse large B‑cell lymphoma

  This trial will try the CRP drug combination (chidamide, rituximab, and polatuzumab vedotin) as first-line treatment for older adults with previously untreated double-expressor DLBCL.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07397832

• Combining pomalidomide, rituximab, orelabrutinib and polatuzumab vedotin for elderly diffuse large B‑cell lymphoma

  This tests whether adding polatuzumab vedotin to a pomalidomide, rituximab and orelabrutinib regimen helps patients aged 70 and older with newly diagnosed diffuse large B‑cell lymphoma.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07072208

• Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

  A group of elderly patients with newly diagnosed diffuse large B-cell lymphoma will try a lighter chemotherapy approach using three targeted drugs to see if it works and is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07012980

• Pola‑R‑GemOx chemotherapy for relapsed/refractory DLBCL in patients who cannot have an autologous transplant

  This trial will test whether adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin helps people with relapsed or refractory DLBCL who are not eligible for autologous stem‑cell transplant.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07001540

• Comparing two treatments for a type of blood cancer called DLBCL

  This study is testing whether a new combination of treatments can help people with a specific type of blood cancer feel better compared to the standard treatment.

  Recruiting at 146 sites Phase 2 Merck Sharp & Dohme LLC · Mobile, Alabama and 147 other locations · NCT06890884

• Mosunetuzumab and Polatuzumab Vedotin with split-dose CHP in older adults with DLBCL

  This phase 2 study tests whether adding Mosunetuzumab subcutaneous and Polatuzumab Vedotin to a split-dose CHP chemotherapy regimen helps elderly, newly diagnosed DLBCL patients who are frail or unfit.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06594939

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people aged 18 to 75 with relapsed or refractory diffuse large B-cell lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhou, Zhejiang · NCT06554600

• Comparing Pola-ZR2 and ZR2 for treating elderly patients with diffuse large B-cell lymphoma

  This study is testing if adding a new drug called polatuzumab vedotin to a standard treatment helps older patients with diffuse large B-cell lymphoma feel better and improve their outcomes.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT06522555

• Treatment for relapsed or refractory follicular lymphoma using two monoclonal antibodies

  This study is testing a combination of two new treatments for people with follicular lymphoma that hasn't responded to previous therapies to see if they can improve their health and survival.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06453044

• Treatment for elderly patients with newly diagnosed diffuse large B cell lymphoma

  This study is testing a new combination treatment for older patients with newly diagnosed diffuse large B cell lymphoma to see if it helps them respond better to therapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06176729

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

• Evaluating Glofitamab Alone or with Other Treatments for Richter's Transformation

  This study is testing if a new treatment called Glofitamab, alone or with other medications, can help people with Richter's Transformation from Chronic Lymphocytic Leukemia feel better.

  Recruiting at 5 sites Phase 2 Dana-Farber Cancer Institute · Atlanta, Georgia and 4 other locations · NCT06043674

• Combining three anti-cancer drugs for treating relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a combination of three cancer drugs to see if they can help people with tough-to-treat diffuse large B-cell lymphoma feel better and respond to treatment.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 7 other locations · NCT06015880

• Treatment for relapsed mantle cell lymphoma using a combination of drugs

  This study is testing a new combination of drugs to see if it can help people with relapsed mantle cell lymphoma who haven't had success with other treatments.

  Recruiting Phase 2 Medical University of Vienna · Vienna · NCT05868395

• Glofitamab and Polatuzumab with R-CHP for high-risk diffuse large B-cell lymphoma

  This will test whether adding the immunotherapies glofitamab and polatuzumab to standard R-CHP chemotherapy helps adults with previously untreated high-risk diffuse large B-cell lymphoma.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT05800366

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of treatments for people with relapsed B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05615636

• Combination treatment for aggressive Non-Hodgkin's Lymphoma

  This study is testing a new combination of treatments for people with aggressive Non-Hodgkin's Lymphoma to see if it can help shrink their tumors when other treatments haven't worked.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT05260957

• Using stem cell transplant and Polatuzumab Vedotin for treating B-cell lymphomas

  This study is testing if a stem cell transplant followed by a new drug called Polatuzumab Vedotin can help people with different types of B-cell lymphomas feel better.

  Recruiting Phase 1/2 New York Medical College · Valhalla, New York · NCT04491370

• Comparing two treatments for elderly patients with diffuse large B-cell lymphoma

  This study is testing whether a new treatment for elderly patients with diffuse large B-cell lymphoma works better than the standard treatment.

  Recruiting at 52 sites Phase 3 Nordic Lymphoma Group · Albury and 68 other locations · NCT04332822

Quick answers

How many clinical trials of Polatuzumab are recruiting right now?

24, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 18 countries. The most sites are in China (11 trials), United States (9 trials), Italy (2 trials), United Kingdom (2 trials), Russia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 17, Phase 3: 2, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →